» Articles » PMID: 15485831

Osteoclast Differentiation is Impaired in the Absence of Inhibitor of Kappa B Kinase Alpha

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2004 Oct 16
PMID 15485831
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Signaling through the receptor activator of nuclear factor kappa B (RANK) is required for both osteoclast differentiation and mammary gland development, yet the extent to which RANK utilizes similar signaling pathways in these tissues remains unclear. Mice expressing a kinase-inactive form of the inhibitor of kappa B kinase alpha (IKK alpha) have mammary gland defects similar to those of RANK-null mice yet have apparently normal osteoclast function. Because mice that completely lack IKK alpha have severe skin and skeletal defects that are not associated with IKK alpha-kinase activity, we wished to directly examine osteoclastogenesis in IKK alpha(-/-) mice. We found that unlike RANK-null mice, which completely lack osteoclasts, IKK alpha(-/-) mice did possess normal numbers of TRAP(+) osteoclasts. However, only 32% of these cells were multinucleated compared with 57% in wild-type littermates. A more profound defect in osteoclastogenesis was observed in vitro using IKK alpha(-/-) hematopoietic cells treated with colony-stimulating factor 1 and RANK ligand (RANKL), as the cells failed to form large, multinucleated osteoclasts. Additionally, overall RANKL-induced global gene expression was significantly blunted in IKK alpha(-/-) cells, including osteoclast-specific genes such as TRAP, MMP-9, and c-Src. IKK alpha was not required for RANKL-mediated I kappa B alpha degradation or phosphorylation of mitogen-activated protein kinases but was required for RANKL-induced p100 processing. Treatment of IKK alpha(-/-) cells with tumor necrosis factor alpha (TNF alpha) in combination with RANKL led to partial rescue of osteoclastogenesis despite a lack of p100 processing. However, the ability of TNF alpha alone or in combination with transforming growth factor beta to induce osteoclast differentiation was dependent on IKK alpha, suggesting that synergy between RANKL and TNFalpha can overcome p100 processing defects in IKK alpha(-/-) cells.

Citing Articles

Nuclear Factor-Kappa B Regulation of Osteoclastogenesis and Osteoblastogenesis.

Boyce B, Li J, Yao Z, Xing L Endocrinol Metab (Seoul). 2023; 38(5):504-521.

PMID: 37749800 PMC: 10613774. DOI: 10.3803/EnM.2023.501.


Casticin suppresses RANKL‑induced osteoclastogenesis and prevents ovariectomy‑induced bone loss by regulating the AKT/ERK and NF‑κB signaling pathways.

Yang F, Su Y, Liang J, Wang K, Lian H, Chen J Int J Mol Med. 2023; 51(5).

PMID: 37052260 PMC: 10198048. DOI: 10.3892/ijmm.2023.5246.


Conditional loss of IKKα in Osterix + cells has no effect on bone but leads to age-related loss of peripheral fat.

Davis J, Pokhrel N, Cox L, Rohatgi N, Faccio R, Veis D Sci Rep. 2022; 12(1):4915.

PMID: 35318397 PMC: 8940989. DOI: 10.1038/s41598-022-08914-6.


The Role of NF-κB in Physiological Bone Development and Inflammatory Bone Diseases: Is NF-κB Inhibition "Killing Two Birds with One Stone"?.

Jimi E, Takakura N, Hiura F, Nakamura I, Hirata-Tsuchiya S Cells. 2019; 8(12).

PMID: 31847314 PMC: 6952937. DOI: 10.3390/cells8121636.


Pharmacological Inhibition of the Skeletal IKKβ Reduces Breast Cancer-Induced Osteolysis.

Marino S, Bishop R, Mollat P, Idris A Calcif Tissue Int. 2018; 103(2):206-216.

PMID: 29455416 PMC: 6061461. DOI: 10.1007/s00223-018-0406-4.